BioMarin talks down worries on gene therapy data differences

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 10, 2019 at 11:52 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,741
    Likes Received:
    3
    via BioMarin Pharmaceutical on Monday laid out its explanation for why Phase 3 results from its closely watched hemophilia A gene therapy appeared to slip from an earlier trial, pointing to differences in steroid use between the two studies.

    article source